Boston Scientific Corporation BSX
- Market cap
- $64.7B
- P/E
- 17.7×
Follow BSX
Boston Scientific Corporation (BSX) Free cash flow
Boston Scientific Corporation's free cash flow for fiscal 2025 was $3.7B, up 38.3% from $2.6B in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.6B. Over the past ten years it has ranged from $8.0M (fiscal 2018) to $3.7B (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. Boston Scientific Corporation ranks 4th of 149 Medical Devices companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $3.7B | 38.30% |
| FY2024 | $2.6B | 47.60% |
| FY2023 | $1.8B | 88.63% |
| FY2022 | $950.0M | (28.57%) |
| FY2021 | $1.3B | 16.26% |
| FY2020 | $1.1B | (17.22%) |
| FY2019 | $1.4B | 17,175.00% |
| FY2018 | $8.0M | (99.28%) |
| FY2017 | $1.1B | 32.57% |
| FY2016 | $835.0M | 88.06% |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $1.3B | 647.95% |
| Mar 2026 | $171.0M | (83.12%) |
| Dec 2025 | $1.0B | (12.82%) |
| Sep 2025 | $1.2B | 2.92% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ABT Abbott Laboratories compare | $7.8B |
| MDT Medtronic PLC compare | $6.1B |
| SYK Stryker Corporation compare | $4.7B |
| BSX Boston Scientific Corporation | $3.6B |
| PHG Koninklijke Philips N.V. compare | $1.8B |
| GEHC GE HealthCare Technologies Inc. compare | $1.6B |
| EW Edwards Lifesciences Corporation compare | $1.4B |
| DXCM DexCom, Inc. compare | $1.4B |
| STE STERIS plc compare | $936.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on BSX
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement